This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| VIG | |
|---|---|
| Name | VIG |
VIG
VIG is a biological product used in medical practice with immunotherapeutic properties. It is administered to modify host responses to pathogens or immune phenomena and is handled within clinical, regulatory, and manufacturing frameworks. Its development and use intersect with public health agencies, academic institutions, blood services, and pharmaceutical manufacturers.
VIG denotes a specific immunoglobulin preparation derived from pooled human plasma collected from screened donors at licensed facilities such as Red Cross, American Red Cross, NHS Blood and Transplant, National Institutes of Health, and national blood services in many countries. Nomenclature for VIG follows regulatory conventions established by agencies including the Food and Drug Administration, European Medicines Agency, World Health Organization, Pharmacopoeia of the United States, and national pharmacopoeias; product names may be trademarked by manufacturers like Grifols, CSL Behring, Takeda, Baxter International, and Octapharma. Classification places VIG among plasma‑derived medicinal products regulated under biologics statutes such as the Biologics Price Competition and Innovation Act and subject to guidelines from organizations like the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.
The conceptual roots of VIG trace to passive immunotherapy milestones including the work of Emil von Behring and Shibasaburo Kitasato on antitoxins, and the institutionalization of plasma fractionation by E.J. Cohn and colleagues during the mid‑20th century. Plasma fractionation and immunoglobulin purification advanced through contributions by manufacturers and researchers at institutions such as Kaiser Permanente, Walter Reed Army Institute of Research, Pasteur Institute, and university laboratories at Harvard Medical School and University of Oxford. Regulatory responses to bloodborne pathogens like HIV/AIDS epidemic and hepatitis C virus outbreaks prompted improvements in donor screening, viral inactivation steps, and surveillance by agencies including Centers for Disease Control and Prevention and World Health Organization.
VIG exerts effects via passive transfer of pooled human immunoglobulins, containing antibodies targeting specific antigens. Its mechanism involves antibody‑mediated neutralization, opsonization, complement activation, and modulation of immune effector cells that engage through Fc receptors characterized in studies at institutions such as Rockefeller University and National Institutes of Health. VIG preparations may contain high titers of antibodies against particular pathogens or antigens due to donor exposure or hyperimmunization campaigns organized by public health entities like Centers for Disease Control and Prevention and European Centre for Disease Prevention and Control. Pharmacodynamic profiling and pharmacokinetic modeling have been developed in research centers including Mayo Clinic, Johns Hopkins University, and Massachusetts General Hospital.
Clinicians utilize VIG for prophylaxis and treatment in contexts overseen by specialty societies such as Infectious Diseases Society of America, American Academy of Pediatrics, European Society of Clinical Microbiology and Infectious Diseases, and public health recommendations from World Health Organization and Centers for Disease Control and Prevention. Indications include post‑exposure prophylaxis for specific viral exposures, passive immunization during outbreaks coordinated with agencies like Public Health England and CDC, and treatment of immune‑mediated dermatologic or hematologic conditions when guided by guidelines from American College of Physicians and European Academy of Dermatology and Venereology. Use is integrated into care pathways in hospitals such as Mayo Clinic, Cleveland Clinic, and tertiary centers associated with universities like University of California, San Francisco.
Adverse effects documented in pharmacovigilance databases maintained by Food and Drug Administration, European Medicines Agency, and national authorities include infusion reactions, hypersensitivity, thromboembolic events, and transmission risks mitigated by viral reduction processes developed by companies such as Grifols and institutions like Pasteur Institute. Contraindications may reference immunoglobulin A deficiency with anti‑IgA antibodies and prior anaphylaxis; management strategies are informed by guidance from American Academy of Allergy, Asthma & Immunology and European Medicines Agency safety communications. Post‑marketing surveillance and case reports in journals affiliated with New England Journal of Medicine, The Lancet, and Journal of the American Medical Association help refine risk profiles.
Production involves plasma collection at donor centers organized by Red Cross, NHS Blood and Transplant, and private plasma centers; fractionation using methods rooted in Cohn process variants; purification and viral removal incorporating solvent/detergent treatment, pasteurization, and nanofiltration developed in collaboration with manufacturers like Baxter International and CSL Behring. Quality control adheres to standards from World Health Organization, European Pharmacopoeia, and United States Pharmacopeia, with lot release testing for potency, sterility, endotoxin, and specific antibody titers performed in GMP facilities certified by national regulatory agencies. Cold chain logistics and traceability systems reference practices endorsed by World Health Organization and standards bodies such as International Organization for Standardization.
Ongoing research at centers including National Institutes of Health, Harvard Medical School, Stanford University, and industry research programs at Takeda and Octapharma explores optimized hyperimmune preparations, monoclonal antibody alternatives, recombinant Fc‑engineered products, and improved viral safety measures. Trials coordinated with networks like NIH Clinical Center and consortia including Global Health Innovative Technology Fund investigate prophylactic strategies during emerging pathogen events such as outbreaks managed by World Health Organization and Centers for Disease Control and Prevention. Future directions emphasize dose optimization, targeted antibody enrichment, expanded indications supported by randomized controlled trials in journals such as New England Journal of Medicine and The Lancet, and integration with precision medicine initiatives at institutions like Broad Institute and Bill & Melinda Gates Foundation‑funded programs.
Category:Immunoglobulins